INDP תחזית צמיחת רווח נקי למניה לשנה הבאה Indaptus Therapeutics Inc

Indaptus Therapeutics is developing a scalable bacterial immuno-oncology platform, monetizing patents through royalties from pharma behemoths. Reviewing the 12-month EPS growth targets on GURU.Markets, we see that the 0.00 level reflects fresh values. Indaptus Therapeutics is implementing a bold method of training the body to fight cancer using inactivated bacteria, targeting growing demand within the early clinical trials segment.

The stability of the biomedical sector and its humanitarian status provide Indaptus Therapeutics (INDP) with a resilient operational backdrop shielded from geopolitical shocks. This projected net income trend chart visualizes daily changes in analysts' consensus estimates for future earnings per share, allowing investors to gauge market optimism and fundamental confidence in the business's capitalization through the lens of expected profit growth.